Long-term effects of neoadjuvant chemotherapy in advanced colon cancer
Author Information
Author(s): Qiancheng Wang, Shiyang Jin, Zeshen Wang, Yuming Ju, Kuan Wang
Primary Institution: Harbin Medical University Cancer Hospital
Hypothesis
Does neoadjuvant chemotherapy improve long-term survival in patients with locally advanced colon cancer based on histological subtype?
Conclusion
Neoadjuvant chemotherapy may improve long-term survival in patients with non-mucinous adenocarcinoma but not in those with mucinous adenocarcinoma or signet ring cell carcinoma.
Supporting Evidence
- Patients with non-mucinous adenocarcinoma treated with neoadjuvant chemotherapy had a 5-year overall survival rate of 76.3%.
- Patients with mucinous adenocarcinoma and signet ring cell carcinoma did not show significant survival differences with neoadjuvant chemotherapy.
- The study included a large cohort of 3,709 patients, enhancing the reliability of the findings.
- Propensity score matching was used to reduce confounding factors between treatment groups.
Takeaway
This study found that giving chemotherapy before surgery can help some patients with colon cancer live longer, especially those with a certain type of cancer.
Methodology
This retrospective study analyzed 3,709 patients with locally advanced colon cancer who underwent curative resection, comparing outcomes between those receiving neoadjuvant chemotherapy and those receiving adjuvant chemotherapy.
Potential Biases
Potential selection bias due to the exclusion of patients with non-R0 resection.
Limitations
The study is retrospective and may have selection bias; it only included patients with R0 resection.
Participant Demographics
Patients were primarily adults aged 18 and older, with a mix of genders and varying tumor characteristics.
Statistical Information
P-Value
.039
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website